Ajanta Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Ajanta Pharma Q2 results FY27 announcement is the next scheduled earnings event for Ajanta Pharma Ltd., a branded generics pharmaceutical company selling in India, Asia and Africa alongside a United States generics business, with strengths in cardiology, dermatology and ophthalmology. The stock traded at Rs 3,552.70 on the NSE on 9 September 2026, down 0.74% from the previous close of Rs 3,579.30, about 6.4% below its 52-week high of Rs 3,796.00 and 52.5% above its 52-week low of Rs 2,329.90.

What makes the Ajanta Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,413.07 crore of revenue and a profit of Rs 260.19 crore, while the most recent quarter on record, Q1 FY27, produced Rs 1,696.86 crore and a profit of Rs 334.22 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Ajanta Pharma Q2 Results FY27 Date?

The Ajanta Pharma Q2 results date for FY27 is not confirmed. As of 9 September 2026, Ajanta Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Ajanta Pharma Q2 results date becomes public through that filing rather than through any advance announcement.

The Ajanta Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Ajanta Pharma.

Ajanta Pharma Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Ajanta Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Ajanta Pharma. The Ajanta Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is the June quarter's step up. Revenue reached Rs 1,696.86 crore in Q1 FY27, well above the Rs 1,483.07 crore of the preceding quarter, and profit rose to Rs 334.22 crore with operating margin improving to 30.41%.

The second is the branded generics engine. India, Asia and Africa branded sales carry better economics than the American generics business, so the geographic mix decides how much of a revenue increase reaches profit.

The third is the September 2025 base of Rs 1,413.07 crore in revenue and Rs 260.19 crore in profit at a 28.60% margin. Growth against that base looks achievable on the current run rate, which shifts attention to whether margin holds above 30%.

Check Ajanta Pharma Ltd. Live Fundamentals on the Univest Screener

Ajanta Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Ajanta Pharma Ltd. reported revenue of Rs 1,696.86 crore in Q1 FY27, up 27.68% from Rs 1,328.98 crore in Q1 FY26, and a profit of Rs 334.22 crore at the net level, up 30.89% from Rs 255.34 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was up 14.42% over the March 2026 quarter figure of Rs 1,483.07 crore, and net profit was up 25.32% from Rs 266.70 crore in Q4 FY26. Operating margin stood at 30.41% in Q1 FY27 against 28.60% in the September 2025 quarter, which is the comparison the Ajanta Pharma Q2 results print will be read against.

Q2 FY26 Base: The Comparison Ajanta Pharma Q2 Results FY27 Must Beat

Ajanta Pharma Ltd. reported revenue of Rs 1,413.07 crore and a profit of Rs 260.19 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Ajanta Pharma Q2 results preview.

Net profit in that base quarter was below the Rs 334.22 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 1,413.07 crore sits below the Rs 1,696.86 crore of the June 2026 quarter, which frames how much sequential movement the Ajanta Pharma Q2 results print needs to show growth.

Ajanta Pharma Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	1,413.07	260.19
Q3 FY26 (Dec 2025)	1,399.81	273.77
Q4 FY26 (Mar 2026)	1,483.07	266.70
Q1 FY27 (Jun 2026)	1,696.86	334.22

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Ajanta Pharma Q2 results preview uses.

Revenue across those four quarters ranged from Rs 1,399.81 crore to Rs 1,696.86 crore, and net profit from Rs 260.19 crore to Rs 334.22 crore. That spread is the honest context for the Ajanta Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Ajanta Pharma Q2 Results FY27

The Ajanta Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Ajanta Pharma has already reported.

Branded Markets Versus United States Generics

Africa and Asia branded sales are prescription-led and less exposed to price erosion, while the American business faces continuous generic price pressure. The balance between them is the main margin variable.

New Launches and Therapy Mix

Cardiology, dermatology and ophthalmology each behave differently through the year. New product introductions in the branded markets are what sustain growth above the underlying market rate.

Strong Returns at a Full Valuation

Ajanta Pharma generates a return on equity of 23.33% with a debt-to-equity ratio of 0.06, and trades at a price-to-earnings ratio of 39.46 against a sector average of 37.99 and 9.89 times book value.

Ajanta Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print

Ajanta Pharma share price today is Rs 3,552.70 on the NSE, down Rs 26.60 or 0.74% from the previous close of Rs 3,579.30 on 9 September 2026, ahead of the Ajanta Pharma Q2 results announcement.

Metric	Value (8 September 2026)
NSE Symbol	AJANTPHARM
Current Market Price	Rs 3,552.70
52-Week High	Rs 3,796.00
52-Week Low	Rs 2,329.90
Market Capitalisation	Rs 44,778 crore
PE Ratio	39.46
Sector PE	37.99
PB Ratio	9.89
EPS (TTM)	Rs 90.82
Book Value per Share	Rs 362.28
Debt to Equity	0.06
Return on Equity	23.33%
50-Day Moving Average	Rs 3,489.93
200-Day Moving Average	Rs 3,029.30
RSI (14)	40.05

The stock trades above both its 50-day average of Rs 3,489.93 and its 200-day average of Rs 3,029.30, with a 14-day RSI of 40.05. None of this is a view on where the shares go once the Ajanta Pharma Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Ajanta Pharma Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Ajanta Pharma Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Ajanta Pharma Q2 results print in proportion.

1. Revenue against the Rs 1,413.07 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 260.19 crore in that same quarter
3. Operating margin against 30.41% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Ajanta Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Ajanta Pharma Q2 Results FY27

The Ajanta Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Ajanta Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Ajanta Pharma Q2 results FY27 print faces a base of Rs 1,413.07 crore in revenue and a profit of Rs 260.19 crore, with the most recent quarter having delivered Rs 1,696.86 crore and a profit of Rs 334.22 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Ajanta Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Ajanta Pharma Q2 Results FY27

What is the Ajanta Pharma Q2 results date for FY27?

Ans. The Ajanta Pharma Q2 results date for FY27 is not confirmed. Ajanta Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Ajanta Pharma Q2 results 2026 cover?

Ans. The Ajanta Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Ajanta Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Ajanta Pharma Q2 results filing also carries the notes to the accounts.

What were the Ajanta Pharma Q1 FY27 results?

Ans. Ajanta Pharma Ltd. reported revenue of Rs 1,696.86 crore in Q1 FY27 and a profit of Rs 334.22 crore at the net level. Revenue was up 27.68% versus Q1 FY26 and net profit was up 30.89% from Rs 255.34 crore in Q1 FY26.

What were Ajanta Pharma Q2 FY26 results in the September 2025 quarter?

Ans. Ajanta Pharma Ltd. reported revenue of Rs 1,413.07 crore and a profit of Rs 260.19 crore in Q2 FY26. Operating margin was 28.60%. Those figures form the base for the Ajanta Pharma Q2 results FY27 comparison.

What are the main Ajanta Pharma Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Ajanta Pharma Q2 results expectations centre on revenue against the Rs 1,413.07 crore base, net profit against a profit of Rs 260.19 crore, operating margin against 30.41% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Ajanta Pharma share price today ahead of the Q2 earnings?

Ans. Ajanta Pharma share price is Rs 3,552.70 on the NSE as of 9 September 2026, down 0.74% from Rs 3,579.30. The stock is about 6.4% below its 52-week high of Rs 3,796.00 and 52.5% above its 52-week low of Rs 2,329.90, at a market capitalisation of Rs 44,778 crore.

Is Ajanta Pharma a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Ajanta Pharma Ltd.. The stock trades at a price-to-book ratio of 9.89 with a return on equity of 23.33%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.